BR112017022666A8 - Preparando resposta à alvocidib por perfilamento mitocondrial - Google Patents
Preparando resposta à alvocidib por perfilamento mitocondrialInfo
- Publication number
- BR112017022666A8 BR112017022666A8 BR112017022666A BR112017022666A BR112017022666A8 BR 112017022666 A8 BR112017022666 A8 BR 112017022666A8 BR 112017022666 A BR112017022666 A BR 112017022666A BR 112017022666 A BR112017022666 A BR 112017022666A BR 112017022666 A8 BR112017022666 A8 BR 112017022666A8
- Authority
- BR
- Brazil
- Prior art keywords
- alvocidib
- response
- mitochondrial profiling
- preparing response
- preparing
- Prior art date
Links
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 title abstract 2
- 229950010817 alvocidib Drugs 0.000 title abstract 2
- 230000002438 mitochondrial effect Effects 0.000 title abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562150138P | 2015-04-20 | 2015-04-20 | |
PCT/US2016/028443 WO2016172214A1 (en) | 2015-04-20 | 2016-04-20 | Predicting response to alvocidib by mitochondrial profiling |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017022666A2 BR112017022666A2 (pt) | 2018-07-17 |
BR112017022666A8 true BR112017022666A8 (pt) | 2022-10-18 |
Family
ID=55863240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017022666A BR112017022666A8 (pt) | 2015-04-20 | 2016-04-20 | Preparando resposta à alvocidib por perfilamento mitocondrial |
Country Status (13)
Country | Link |
---|---|
US (4) | US9901574B2 (pt) |
EP (2) | EP3611506B1 (pt) |
JP (1) | JP6851978B2 (pt) |
KR (1) | KR20180018507A (pt) |
CN (1) | CN107995863A (pt) |
AU (1) | AU2016252609B2 (pt) |
BR (1) | BR112017022666A8 (pt) |
CA (1) | CA2982928A1 (pt) |
HK (1) | HK1251655A1 (pt) |
IL (1) | IL255029B (pt) |
MX (1) | MX2017013383A (pt) |
RU (1) | RU2717829C2 (pt) |
WO (1) | WO2016172214A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180018507A (ko) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측 |
EP3298021B1 (en) | 2015-05-18 | 2019-05-01 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs having increased bioavailability |
KR20180034538A (ko) | 2015-08-03 | 2018-04-04 | 톨레로 파마수티컬스, 인크. | 암의 치료를 위한 병행 요법 |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
KR20190099260A (ko) * | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
US11541073B2 (en) * | 2018-01-12 | 2023-01-03 | Children's Hospital Medical Center | Methods of attenuating an immune response by inhibition of BFL1 |
WO2019200243A1 (en) * | 2018-04-13 | 2019-10-17 | Tolero Pharmaceuticals, Inc. | Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer |
US20210277037A1 (en) * | 2018-06-21 | 2021-09-09 | Sumitomo Dainippon Pharma Oncology, Inc. | Deuterated alvocidib and alvocidib prodrugs |
TW202344250A (zh) * | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
EP3890749A4 (en) | 2018-12-04 | 2022-08-03 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT |
WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
WO2021007314A2 (en) * | 2019-07-08 | 2021-01-14 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of cancer |
WO2021007316A1 (en) | 2019-07-08 | 2021-01-14 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of cancer |
WO2021104442A1 (en) * | 2019-11-27 | 2021-06-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway |
JP2023504515A (ja) | 2019-12-05 | 2023-02-03 | スミトモ ファーマ オンコロジー, インコーポレイテッド | 骨髄異形成症候群の処置のための併用療法 |
Family Cites Families (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2338043A1 (fr) | 1976-01-13 | 1977-08-12 | Delmar Chem | Derives de 4-arylpiperidine et procedes de production |
US4132710A (en) | 1976-12-20 | 1979-01-02 | Ayerst, Mckenna And Harrison, Ltd. | [2]Benzopyrano[3,4-c]pyridines and process therefor |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IN164232B (pt) | 1986-04-11 | 1989-02-04 | Hoechst India | |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP2691986B2 (ja) | 1987-08-28 | 1997-12-17 | チッソ株式会社 | ピリジン骨格を有する光学活性化合物の製造法 |
DE3743824C2 (de) | 1987-12-23 | 1997-03-06 | Hoechst Ag | Verfahren zur enzymatischen Racematspaltung von racemischen Alkoholen mit/in Vinylestern durch Umesterung |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3836676A1 (de) | 1988-10-28 | 1990-05-03 | Hoechst Ag | Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel |
US5284856A (en) | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JPH0641075A (ja) | 1990-09-01 | 1994-02-15 | Kazuo Achinami | 新規な1,4−ジヒドロピリジン化合物及びその製造方法 |
EP0507278A3 (en) | 1991-04-02 | 1993-12-15 | Hoechst Ag | Immobilised biocatalyser, its preparation and use for ester synthesis in a column reactor |
CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
GB9422836D0 (en) | 1994-11-11 | 1995-01-04 | Wainscoat James | Monitoring malignant disease |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
PT821671E (pt) | 1995-04-20 | 2001-04-30 | Pfizer | Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
EP0845043B1 (en) | 1995-07-28 | 2007-06-27 | Marie Curie Cancer Care | Transport proteins and their uses |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Hoffmann La Roche | Matrix-metalloprotease Inhibitoren |
AU2195297A (en) | 1996-02-20 | 1997-09-02 | Sloan-Kettering Institute For Cancer Research | Combinations of pkc inhibitors and therapeutic agents for treating cancers |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
US6087366A (en) | 1996-03-07 | 2000-07-11 | The Trustees Of Columbia University In The City Of New York | Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
DE69718472T2 (de) | 1996-07-13 | 2003-11-06 | Glaxo Group Ltd | Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren |
ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
TR199900066T2 (xx) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri |
TR199900387T2 (xx) | 1996-08-23 | 1999-04-21 | Pfizer Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
CA2277100C (en) | 1997-01-06 | 2005-11-22 | Pfizer Inc. | Cyclic sulfone derivatives |
EA002594B1 (ru) | 1997-02-03 | 2002-06-27 | Пфайзер Продактс Инк. | Производные арилсульфониламиногидроксамовой кислоты |
KR20000070751A (ko) | 1997-02-05 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 세포 증식 억제제로서의 피리도[2,3-d]피리미딘 및 4-아미노피리미딘 |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
CN1247531A (zh) | 1997-02-11 | 2000-03-15 | 辉瑞大药厂 | 芳基磺酰基异羟肟酸衍生物 |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
WO1998054093A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
PT1003720E (pt) | 1997-08-08 | 2004-07-30 | Pfizer Prod Inc | Derivados de acido ariloxiarilsulfonilamino hidroxamico |
AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
JP2001524301A (ja) | 1997-09-17 | 2001-12-04 | ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ | 新規治療用分子 |
AU9402898A (en) | 1997-09-26 | 1999-04-23 | Washington University | Cell death agonists |
WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
IL135636A0 (en) | 1997-11-11 | 2001-05-20 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
DE19802449A1 (de) | 1998-01-23 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin |
US6437136B2 (en) | 1998-01-23 | 2002-08-20 | Aventis Pharma Deutschland Gmbh | Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
DE19809649A1 (de) | 1998-03-06 | 1999-09-09 | Hoechst Marion Roussel De Gmbh | Verfahren zur enzymatischen Enantiomeren-Trennung von 3(R)- und 3(S)-Hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridin bzw. der Carbonsäureester |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
CA2314156C (en) | 1998-05-29 | 2010-05-25 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
FR2780056B1 (fr) | 1998-06-18 | 2000-08-04 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives de la 4-phenyl-1-2 3,6-tetrahydropyridine et les produits imtermediaires mis en oeuvre |
CA2338638C (en) | 1998-07-30 | 2009-03-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
US6268499B1 (en) | 1998-08-10 | 2001-07-31 | Hoffman-La Roche Inc. | Process and intermediates for preparation of substituted piperidine-epoxides |
WO2000012071A2 (de) | 1998-08-29 | 2000-03-09 | Miklos Ghyczy | Pharmazeutisches und/oder diätetisches produkt |
PT1004578E (pt) | 1998-11-05 | 2004-06-30 | Pfizer Prod Inc | Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
WO2000059526A1 (en) | 1999-04-07 | 2000-10-12 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
WO2001012661A2 (en) | 1999-08-16 | 2001-02-22 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health | RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS |
US6821990B2 (en) | 2000-01-18 | 2004-11-23 | Aventis Pharma Deutschland Gmbh | Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one |
US6576647B2 (en) | 2000-01-18 | 2003-06-10 | Aventis Pharmaceuticals Inc. | Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one |
CN1329390C (zh) | 2000-02-15 | 2007-08-01 | 苏根公司 | 吡咯取代的2-二氢吲哚酮蛋白激酶抑制剂 |
WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
AU2002228849A1 (en) | 2000-12-08 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Semicarbazides and their uses as cyclin dependent kinase inhibitors |
WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
AU2002303164A1 (en) | 2001-03-23 | 2002-10-08 | Protarga, Inc. | Fatty amine drug conjugates |
AU2002305099A1 (en) | 2001-03-23 | 2002-10-08 | Protarga, Inc. | Fatty alcohol drug conjugates |
WO2003027237A2 (en) | 2001-09-24 | 2003-04-03 | Blood Center Research Foundation | Method of modulating or examining ku70 levels in cells |
KR20030026069A (ko) | 2001-09-24 | 2003-03-31 | 주식회사 엘지생명과학 | 티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물 |
WO2003040168A2 (en) | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
US7247700B2 (en) | 2001-12-31 | 2007-07-24 | Dana Farber Cancer Institute, Inc. | BID polypeptides and methods of inducing apoptosis |
SI3483183T1 (sl) | 2002-03-01 | 2021-08-31 | Immunomedics, Inc. | Imunokonjugat ki obsega humanizirana RS7 protitelesa |
US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7417055B2 (en) | 2003-04-25 | 2008-08-26 | Gilead Sciences, Inc. | Kinase inhibitory phosphonate analogs |
GB0315259D0 (en) | 2003-06-30 | 2003-08-06 | Cyclacel Ltd | Use |
CN1302004C (zh) | 2003-08-22 | 2007-02-28 | 浙江海正药业股份有限公司 | 一种阿糖胞苷的制备方法 |
ES2437567T3 (es) | 2003-11-05 | 2014-01-13 | Dana-Farber Cancer Institute, Inc. | Péptidos alfa helicoidales estabilizados y utilizaciones de los mismos |
WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
WO2006101846A1 (en) | 2005-03-16 | 2006-09-28 | Aventis Pharmaceuticals Inc. | Dosing regimen of flavopiridol for treating cancer in particular cll |
WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
US7750000B2 (en) | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
WO2007123791A2 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
EP2026805A1 (en) | 2006-05-08 | 2009-02-25 | Astex Therapeutics Limited | Pharmaceutical combinations of diazole derivatives for cancer treatment |
US9360473B2 (en) | 2006-08-16 | 2016-06-07 | Eutropics Pharmaceuticals, Inc. | Assay system to identify therapeutic agents |
WO2008106635A1 (en) | 2007-03-01 | 2008-09-04 | Supergen, Inc. | Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors |
GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
JP5688288B2 (ja) | 2007-05-15 | 2015-03-25 | ピラマル エンタープライジーズ リミテッド | がんの処置のための相乗的な医薬の組合せ |
US20090030005A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
CA2700925C (en) | 2007-09-26 | 2016-08-23 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
EP2649997B1 (en) | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
TWI378781B (en) | 2008-03-12 | 2012-12-11 | Jung Tang Huang | A belt integrated with stress sensing and output reaction |
US8168755B2 (en) | 2008-05-07 | 2012-05-01 | Eutropics Pharmaceuticals, Inc. | Antibodies specific to heterodimers of Bcl-2 family and uses thereof |
JP6006938B2 (ja) | 2008-06-09 | 2016-10-12 | サイクラセル リミテッド | スパシタビン(cndac)と、デシタビン及びプロカイン等のdnaメチルトランスフェラーゼ阻害剤との組合せ |
MX2011008488A (es) | 2009-02-11 | 2011-10-24 | Abbott Lab | Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2. |
DK3903829T3 (da) | 2009-02-13 | 2023-06-26 | Immunomedics Inc | Immunkonjugater med en intracellulær spaltelig binding |
WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
US20130011393A1 (en) | 2010-01-12 | 2013-01-10 | Johnathan Mark Lancaster | Bad pathway gene signature |
US8372819B2 (en) | 2010-04-11 | 2013-02-12 | Salk Institute For Biological Studies | Methods and compositions for targeting skip |
BR112012029057A2 (pt) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | composições e métodos de tratamento de leucemia |
SG180031A1 (en) | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
EP2684167B1 (en) | 2011-03-08 | 2020-09-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
JP6200884B2 (ja) | 2011-06-14 | 2017-09-20 | ノバルティス アーゲー | 骨髄増殖性腫瘍などの癌の治療におけるパノビノスタットおよびルキソリチニブの組合せ |
EP2561867A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
US9012215B2 (en) | 2011-09-22 | 2015-04-21 | The Johns Hopkins University | Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research |
US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
WO2013082660A1 (en) | 2011-12-09 | 2013-06-13 | Alfred Health | Prediction method |
WO2013138702A2 (en) | 2012-03-15 | 2013-09-19 | Bristol-Myers Squibb Company | Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway |
AU2013235425B2 (en) | 2012-03-20 | 2017-09-21 | Dana Farber Cancer Institute, Inc. | Inhibition of MCL-1 and/or BFL-1/A1 |
JP2015519565A (ja) | 2012-05-10 | 2015-07-09 | ユートロピクス ファーマシューティカルズ, インコーポレイテッド | がんに対する補助的機能診断テスト |
KR101914820B1 (ko) | 2012-05-11 | 2018-11-02 | 모멘텀 다이나믹스 코오퍼레이션 | 조정가능 리액턴스를 생성하기 위한 방법 및 장치 |
WO2013182519A1 (en) | 2012-06-04 | 2013-12-12 | Universitaet Basel | Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer |
WO2013188355A1 (en) | 2012-06-12 | 2013-12-19 | Merck Sharp & Dohme Corp. | Cdk inhibitor for treating refractory chronic lymphocytic leukemia |
US20150322479A1 (en) | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
US20150133450A1 (en) | 2012-06-20 | 2015-05-14 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
JP6352924B2 (ja) | 2012-09-19 | 2018-07-04 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ダイナミックbh3プロファイリング |
US9241941B2 (en) | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
AU2013329311A1 (en) | 2012-10-09 | 2015-04-30 | Igenica Biotherapeutics, Inc. | Anti-C16orf54 antibodies and methods of use thereof |
US20140287932A1 (en) | 2012-10-25 | 2014-09-25 | Whitehead Institute For Biomedical Research | Super-enhancers and methods of use thereof |
US20160178612A1 (en) | 2013-07-18 | 2016-06-23 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
WO2015042249A1 (en) | 2013-09-19 | 2015-03-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
WO2015047510A1 (en) | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
US10640803B2 (en) | 2013-10-30 | 2020-05-05 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
CN105849110B (zh) | 2013-11-08 | 2019-08-02 | 达纳-法伯癌症研究所有限公司 | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 |
WO2015130585A1 (en) | 2014-02-28 | 2015-09-03 | Merck Sharp & Dohme Corp. | Method for treating cancer |
WO2015161247A1 (en) | 2014-04-17 | 2015-10-22 | Igenica Biotherapeutics, Inc. | Humanized anti-c16orf54 antibodies and methods of use thereof |
CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US10300073B2 (en) | 2014-10-14 | 2019-05-28 | The Regents Of The University Of California | Use of CDK9 and BRD4 inhibitors to inhibit inflammation |
CN107205959B (zh) | 2014-11-07 | 2021-02-12 | 大日本住友制药肿瘤学公司 | 靶向在超增强子区域的转录控制的方法 |
AU2016206882B2 (en) | 2015-01-12 | 2022-03-10 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
CA2979999A1 (en) | 2015-03-18 | 2016-09-22 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
EP3274467A4 (en) | 2015-03-24 | 2018-10-31 | Eutropics Pharmaceuticals, Inc. | Surrogate functional biomarker for solid tumor cancer |
WO2016161248A1 (en) | 2015-04-02 | 2016-10-06 | Tolero Pharmaceuticals, Inc. | Targeting pim kinases in combination with btk inhibition |
KR20180018507A (ko) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측 |
AU2016253957C1 (en) | 2015-04-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
EP3298021B1 (en) | 2015-05-18 | 2019-05-01 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs having increased bioavailability |
KR20180034538A (ko) | 2015-08-03 | 2018-04-04 | 톨레로 파마수티컬스, 인크. | 암의 치료를 위한 병행 요법 |
WO2017075349A2 (en) | 2015-10-30 | 2017-05-04 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
CN105919955A (zh) | 2016-06-13 | 2016-09-07 | 佛山市腾瑞医药科技有限公司 | 一种鲁索利替尼制剂及其应用 |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
WO2019200243A1 (en) | 2018-04-13 | 2019-10-17 | Tolero Pharmaceuticals, Inc. | Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer |
-
2016
- 2016-04-20 KR KR1020177033123A patent/KR20180018507A/ko not_active Application Discontinuation
- 2016-04-20 CN CN201680023137.6A patent/CN107995863A/zh active Pending
- 2016-04-20 US US15/134,051 patent/US9901574B2/en active Active
- 2016-04-20 EP EP19199788.1A patent/EP3611506B1/en active Active
- 2016-04-20 CA CA2982928A patent/CA2982928A1/en active Pending
- 2016-04-20 MX MX2017013383A patent/MX2017013383A/es unknown
- 2016-04-20 EP EP16720024.5A patent/EP3286564A1/en not_active Withdrawn
- 2016-04-20 RU RU2017140030A patent/RU2717829C2/ru active
- 2016-04-20 JP JP2017554864A patent/JP6851978B2/ja active Active
- 2016-04-20 AU AU2016252609A patent/AU2016252609B2/en active Active
- 2016-04-20 BR BR112017022666A patent/BR112017022666A8/pt active Search and Examination
- 2016-04-20 WO PCT/US2016/028443 patent/WO2016172214A1/en active Application Filing
-
2017
- 2017-10-15 IL IL255029A patent/IL255029B/en unknown
-
2018
- 2018-08-27 HK HK18111001.4A patent/HK1251655A1/zh unknown
- 2018-09-14 US US16/132,270 patent/US10357488B2/en active Active
-
2019
- 2019-05-29 US US16/425,826 patent/US10624880B2/en active Active
-
2020
- 2020-03-10 US US16/814,398 patent/US20210052568A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3611506B1 (en) | 2021-11-17 |
RU2017140030A (ru) | 2019-05-20 |
IL255029B (en) | 2022-03-01 |
WO2016172214A1 (en) | 2016-10-27 |
US20210052568A1 (en) | 2021-02-25 |
BR112017022666A2 (pt) | 2018-07-17 |
AU2016252609B2 (en) | 2022-06-30 |
CA2982928A1 (en) | 2016-10-27 |
JP6851978B2 (ja) | 2021-03-31 |
RU2717829C2 (ru) | 2020-03-26 |
RU2017140030A3 (pt) | 2019-09-27 |
CN107995863A (zh) | 2018-05-04 |
US20160303101A1 (en) | 2016-10-20 |
US9901574B2 (en) | 2018-02-27 |
MX2017013383A (es) | 2017-12-07 |
US20190030017A1 (en) | 2019-01-31 |
US10624880B2 (en) | 2020-04-21 |
EP3286564A1 (en) | 2018-02-28 |
AU2016252609A1 (en) | 2017-11-02 |
EP3611506A1 (en) | 2020-02-19 |
US20190282557A1 (en) | 2019-09-19 |
JP2018516245A (ja) | 2018-06-21 |
KR20180018507A (ko) | 2018-02-21 |
IL255029A0 (en) | 2017-12-31 |
HK1251655A1 (zh) | 2019-02-01 |
US10357488B2 (en) | 2019-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017022666A2 (pt) | preparando resposta à alvocidib por perfilamento mitocondrial | |
BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
BR112017028353A2 (pt) | anticorpos para cd40 com atividade agonista melhorada | |
EP3146051B8 (en) | Huntington's disease therapeutic compounds | |
BR112016007467A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112015004029A2 (pt) | Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
MA41169A (fr) | Composés antibactériens à large spectre d'activité | |
PT2994160T (pt) | Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada | |
CL2017000312A1 (es) | Elección de microarn como diana para trastornos metabólicos | |
CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
DK3463351T3 (da) | Behandling til parkinsons sygdom | |
BR112015024860A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
BR112016028918A2 (pt) | tratamento de hipertrigliceridemia grave | |
FR3038827B1 (fr) | Ensemble d’instrumentation chirurgicale | |
BR112017003334A8 (pt) | Variantes de desintegrina e usos farmacêuticos destas | |
BR112017005533A2 (pt) | compostos e métodos | |
MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
GB2540076A (en) | Medical data management system | |
BR112017020783A2 (pt) | tratamento de dor | |
IT201700110997A1 (it) | Guida perfezionata per cassetti | |
FR3026520B1 (fr) | Processus d'enregistrement de tracabilite | |
FR3024347B1 (fr) | Dispositif de surveillance medicale d'un patient en particulier souffrant d'un diabete. | |
DK3412339T3 (da) | Indretning til fototerapi eller Grovers sygdom | |
UA34721S (uk) | Наочний посібник «імітатор закритого перелому передпліччя» |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: BOSTON BIOMEDICAL, INC. (US) |
|
B25D | Requested change of name of applicant approved |
Owner name: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: SUMITOMO PHARMA ONCOLOGY, INC. (US) |
|
B25G | Requested change of headquarter approved |
Owner name: SUMITOMO PHARMA ONCOLOGY, INC. (US) |